Optimer's Dificid paves path for orals with CMS NTAP status
This article was originally published in Scrip
Executive Summary
It took investors a few hours on 2 August to catch on to the significance of the win Optimer Pharmaceuticals scored with the US Centers for Medicare & Medicaid Services (CMS) in nabbing a new technology add-on payment (NTAP) designation on the firm's oral antibiotic Dificid (fidaxomicin), but by afternoon, the company's shares had climbed as high as 14.7%.